Syndecan-1 structure-function analysis in relation to iron metabolism - Project Summary/Abstract
Iron is an essential trace mineral involved in vital cellular and systemic functions. Humans and other
vertebrates require a sufficient iron supply to carry out essential metabolic functions and oxygen transport
while maintaining homeostatic iron levels to prevent iron toxicity. Organismal iron content is controlled by
dietary absorption, iron partitioning in erythrocytes, iron recycling by macrophages, and iron storage in
hepatocytes. Precise machinery has evolved to conserve iron stores and regulate iron delivery to tissues. A
critical member of this system is hepcidin, a liver-derived peptide hormone. Hepcidin is a master regulator of
systemic iron homeostasis through its ability to negatively regulate ferroportin, the sole known mammalian
iron-exporter in the cell. Hepcidin synthesis is activated physiologically by elevated serum iron level and
pathologically by inflammation and infection. Hepcidin expression is repressed by increased erythropoietic
demand. Heparan sulfate (HS), a prominent glycan part of the cell glycocalyx, was recently established as a
critical component of hepcidin regulation. Inhibition of HS biosynthesis in hepatoma cells, primary human
hepatocytes, and mice reduced baseline and stimulated hepcidin expression and worsened the
pathophysiology characteristic of anemia of inflammation. Preliminary studies have identified Syndecan-1
(SDC-1), the primary heparan sulfate proteoglycan (HSPG) in the liver, as a novel cell surface receptor
involved in hepcidin regulation. Genetic and pharmacological inactivation of SDC-1 demonstrated that
hepcidin expression is SDC-1-dependent in human hepatoma models. However, its precise mode of action
remains to be elucidated. The proposed study will (i) validate SDC-1 as the key HSPG that regulates basal
and inducible hepcidin expression, identifying a novel arm of iron homeostasis modulation, (ii) elucidate the
mechanism by which SDC-1 regulates hepcidin in vitro which can provide novel insights into the control of
iron homeostasis and (iii) use in vivo liver-specific SDC-1 inactivation to study the impact of SDC-1
depletion and structural alteration on systemic iron homeostasis. The overarching goal of this proposal is to
evaluate the relationship of Syndecan-1 structure to iron metabolism, with the long-range goal of defining
new potential targets to reduce the risk of iron-loading disorders, such as hemochromatosis and anemia of
inflammation.